---
canonical_name: Centrophenoxine
alternate_names: Meclofenoxate, Centrophenoxin, Lucidril, Helfergin, Cerutil, ANP 235, Acephen, Analux, DMAE p-chlorophenoxyacetate
canonical_topic: Centrophenoxine for Health & Longevity
short_topic_lc: centrophenoxine
creation_date: 2026-0629-0402
creator_ai_fullname: Opus 4.8
---
# Centrophenoxine for Health & Longevity
Evidence Review created on 06/29/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8
**Also known as:** Meclofenoxate, Centrophenoxin, Lucidril, Helfergin, Cerutil, ANP 235, Acephen, Analux, DMAE p-chlorophenoxyacetate
## Motivation
Centrophenoxine (also known as meclofenoxate) is a synthetic compound first made in France in the late 1950s. It joins two parts: dimethylaminoethanol, a substance the body can convert toward acetylcholine, a chemical messenger important for memory; and a plant-growth-related acid that appears to help the first part enter cells and the brain. It is taken by mouth and has long been used in several countries as a prescription treatment for age-related memory decline.
What draws longevity-minded people to it is a striking older observation: in aged animals, it reduced the buildup of lipofuscin, a brownish "age pigment" that accumulates in long-lived cells such as neurons over a lifetime. Researchers proposed that clearing this debris and protecting cell membranes from oxidative damage might restore some lost function. A handful of small, dated human studies in older adults reported modest gains on memory tasks.
This review examines what is known about centrophenoxine through a health and longevity lens: how it is thought to work, what the human and animal evidence does and does not show, its safety profile, and the practical and regulatory questions surrounding its unapproved status.
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
## Recommended Reading
This section lists high-quality, accessible overviews that discuss centrophenoxine by name and in depth, to orient the reader before the detailed evidence sections.
* [Centrophenoxine](https://nootropicsexpert.com/centrophenoxine/) - Tomen
A detailed, well-referenced practitioner overview covering mechanism, the dosing range used in the nootropic community, and a plain-language summary of the older human and animal studies, useful for understanding how the compound is actually used.
* [Centrophenoxine](https://www.alzdiscovery.org/cognitive-vitality/ratings/centrophenoxine) - Alzheimer's Drug Discovery Foundation
The Cognitive Vitality team's structured rating weighs the clinical and aging evidence specifically for brain health and longevity, giving a sober, conflict-free assessment of how thin the human data actually are.
* [Centrophenoxine Research, Benefits, and Side effects](https://lifespan.io/topic/why-people-use-centrophenoxine-as-a-nootropic/) - Stephen Rose
A longevity-focused explainer that frames the lipofuscin and membrane-aging rationale in the context of the broader aging field and flags the gap between mechanistic promise and clinical proof.
* [Centrophenoxine: A True Life Extension Drug?](https://www.antiaging-systems.com/articles/centrophenoxine-a-true-life-extension-drug/) - South
A long-form essay by James South summarizing the classic Hungarian and animal lifespan and lipofuscin work, valuable for tracing the original longevity argument back to its primary sources rather than later dismissals.
* [Rick Rosner's Science-Based Longevity](https://www.lifeextension.com/magazine/2015/4/rick-rosner) - Downey
A Life Extension Magazine interview in which centrophenoxine is named among the long-term brain-maintenance compounds in a science-based longevity regimen, useful as a priority-source illustration of how it is positioned within a broader longevity protocol.
Note: Among the priority experts, only Life Extension Magazine carried content naming centrophenoxine in a longevity context (included above); no content discussing centrophenoxine by name could be found from Rhonda Patrick, Peter Attia, Andrew Huberman, or Chris Kresser. The remaining four items are drawn from the next-highest-quality eligible overviews, each from a distinct source.
## Grokipedia
* [Meclofenoxate](https://grokipedia.com/page/Meclofenoxate) - Grokipedia
Grokipedia's dedicated article covers the compound's chemistry, history as a 1950s nootropic, proposed mechanisms, and regulatory status, providing a broad encyclopedic entry point to the topic.
## Examine
* [Centrophenoxine](https://examine.com/supplements/centrophenoxine/) - Examine
Examine's dedicated page summarizes centrophenoxine as a better-absorbed relative of DMAE (dimethylaminoethanol, a compound the body can use toward acetylcholine) and notes the limited human evidence for cognition in the elderly, with links to the underlying studies.
## ConsumerLab
No dedicated ConsumerLab article or product review exists for centrophenoxine. ConsumerLab focuses its independent testing on widely sold dietary supplements; centrophenoxine is an unapproved drug rather than a mainstream supplement, so it is referenced only in passing within broader brain-health overviews and is not covered as its own reviewed page.
## Systematic Reviews
No systematic reviews or meta-analyses dedicated specifically to centrophenoxine were identified; the papers below are broader systematic reviews in which centrophenoxine is one of several agents evaluated, included here because they represent the only systematic-review-level appraisal of its clinical effects.
* [Cholinergic medication for antipsychotic-induced tardive dyskinesia](https://pubmed.ncbi.nlm.nih.gov/29553158/) - Tammenmaa-Aho et al., 2018
This Cochrane review evaluates cholinergic drugs, including meclofenoxate, for an antipsychotic-induced movement disorder; it found too few, too small trials to draw conclusions, illustrating how thin and low-quality the controlled evidence for this drug class remains.
* [Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/15610922/) - Tammenmaa et al., 2004
An earlier meta-analysis of randomized controlled trials of cholinergic agents (a class that includes meclofenoxate) for the same movement disorder, reaching a similarly inconclusive verdict and underscoring the absence of robust pooled efficacy data.
## Mechanism of Action
Centrophenoxine is a molecular pairing of two parts that separate after it is absorbed. The first is dimethylaminoethanol (DMAE), a compound the body can use as a building block on the pathway toward acetylcholine (a chemical messenger nerve cells use to signal, central to attention and memory). The second is para-chlorophenoxyacetic acid (pCPA), a plant-growth-related acid thought to act mainly as a carrier that improves how well DMAE crosses cell membranes and the blood-brain barrier (the protective filter shielding the brain). Several mechanisms have been proposed, and they are not all firmly established.
* **Cholinergic support** — By delivering DMAE, centrophenoxine may modestly raise the supply of material for acetylcholine synthesis, potentially supporting cholinergic signaling that declines with age.
* **Free-radical scavenging and membrane protection** — Centrophenoxine acts as a scavenger of the hydroxyl radical (a highly reactive, damaging oxygen species). The "membrane hypothesis of aging," developed by Imre Zs.-Nagy, proposes that this scavenging protects cell membrane proteins and lipids, helping cells retain water and potassium they lose with age.
* **Lipofuscin reduction** — In aged animals, centrophenoxine reduced accumulation of lipofuscin, the "age pigment" of oxidized lipid-protein debris that builds up in neurons and other long-lived cells. Whether removing this pigment improves cell function, or is merely a marker of reduced oxidative load, remains debated.
* **Glucose and oxygen utilization** — Older studies reported increased cerebral glucose uptake and oxygen consumption, suggesting enhanced brain metabolism, though these findings are dated and not consistently replicated.
A competing interpretation holds that lipofuscin clearance is a cosmetic readout rather than a functional benefit, and that the cholinergic contribution from a tolerable dose is too small to matter clinically. Both views are represented in the literature, and neither has been settled by modern controlled work.
Regarding key pharmacological properties: centrophenoxine is rapidly hydrolyzed (split by water) in plasma, so the parent compound has a very short half-life — on the order of minutes — while the released DMAE and pCPA fragments persist longer and are considered the active species. It is not highly tissue-selective; DMAE distributes broadly, with the brain a target of interest. Metabolism proceeds chiefly through esterase enzymes (which cleave the ester bond) in blood and tissues rather than through the liver's cytochrome P450 (CYP) system (the main family of drug-metabolizing liver enzymes), so classic CYP-based drug interactions are not a prominent feature.
## Historical Context & Evolution
* **Original intended use** — Centrophenoxine was synthesized in France around 1959 and introduced clinically (as Lucidril) for age-related cognitive decline, the after-effects of stroke and head injury, and various forms of dementia. It became one of the earliest agents in the category later termed "nootropics."
* **Path to longevity interest** — Interest broadened from symptom treatment toward aging biology after experiments, notably by Kalidas Nandy and later by Imre Zs.-Nagy's group in Debrecen, Hungary, reported that the drug reduced lipofuscin in the brains of aged animals and improved their learning. Zs.-Nagy embedded these findings in his "membrane hypothesis of aging," positioning centrophenoxine as a membrane-protective, hydroxyl-radical-scavenging intervention rather than merely a memory drug.
* **What the historical research actually showed** — The animal work consistently documented lower neuronal lipofuscin and, in several studies, faster maze learning in old, treated animals versus untreated controls. Some rodent studies also reported modest increases in survival. In humans, small double-blind trials in the 1970s–1990s reported gains on specific memory measures (for example, delayed recall) in healthy elderly and mixed results in dementia, alongside reports of good tolerability.
* **Evolution of scientific opinion** — Enthusiasm cooled as the field recognized that the human trials were small, heterogeneous, and often statistically underpowered, and that lipofuscin reduction had not been clearly tied to functional gain. Regulatory approval never materialized in markets such as the United States. At the same time, the drug remained prescribed in several countries, and modern molecular work (for example, transcriptome studies in killifish and aggregation studies in alpha-synuclein, a protein implicated in Parkinson's disease) has revived narrow mechanistic interest. The current standing is best described as unsettled rather than closed: the original findings were never overturned by contradictory high-quality trials, but neither have they been confirmed by modern, adequately powered studies.
## Expected Benefits
The benefits below are framed for risk-aware adults considering centrophenoxine specifically as a longevity and cognitive-resilience intervention. Evidence is generally old, from small trials, so most grades are modest.
### Low 🟩
#### Memory Support in Older Adults
Small double-blind trials in healthy elderly and in people with mild-to-moderate dementia reported improvements on specific memory measures, most consistently delayed free recall, the ability to retrieve newly learned material after a gap. The proposed mechanism is cholinergic support plus reduced oxidative load on aging neurons. The evidence base is several small randomized trials (commonly 50–75 participants) conducted decades ago with heterogeneous designs; effects were narrow, did not extend uniformly across all cognitive domains, and have not been confirmed by modern adequately powered studies.
**Magnitude:** In a 9-month double-blind trial of healthy elderly (≈74 participants, 600 mg twice daily), the treated group outperformed placebo specifically on delayed free recall; absolute effect sizes were modest and not consistently reported across domains.
#### Reduction of Lipofuscin ("Age Pigment")
In aged animals, centrophenoxine reduced the accumulation of lipofuscin in neurons of the cortex and hippocampus, and one small human trial reported increased intracellular water content consistent with the membrane hypothesis of aging. The proposed mechanism is hydroxyl-radical scavenging and membrane protection slowing the formation of oxidized lipid-protein debris. The evidence is primarily animal histology plus mechanistic human biomarker data; whether pigment clearance translates into preserved function or longer healthspan in humans is unproven.
**Magnitude:** Animal studies show visibly reduced neuronal lipofuscin after weeks-to-months of treatment; a human trial reported a 2.2–2.5% increase in average intracellular water by weight in the treated group. No human functional or lifespan endpoint has been quantified.
### Speculative 🟨
#### Lifespan Extension
Some rodent experiments reported modest increases in average survival in treated aged animals, and proponents have framed centrophenoxine as a candidate "life-extension drug." No controlled studies have isolated such a basis in humans; the human rationale rests entirely on animal survival data and the mechanistic membrane and lipofuscin arguments. This benefit is therefore mechanistic and anecdotal only.
#### Neuroprotection in Neurodegenerative Disease
In vitro work showed that meclofenoxate reduced aggregation of alpha-synuclein (the protein that forms the deposits seen in Parkinson's disease), and animal models reported improved dopamine levels and motor function. These are laboratory and animal findings with no controlled human neurodegenerative-disease trials; the basis for any human benefit is mechanistic only.
#### General Anti-Oxidant and Cellular "Rejuvenation" Effects
Centrophenoxine has been promoted for broad cellular rejuvenation, glucose and oxygen utilization in the brain, and overall vitality. These claims derive from older animal metabolic studies and the free-radical-scavenging mechanism rather than from controlled human outcome data, and should be regarded as mechanistic or anecdotal.
## Benefit-Modifying Factors
* **Baseline cognitive status:** The clearest signals appeared in older adults with measurable memory decline rather than in young, healthy people; benefit may be smaller or undetectable in those without an existing deficit, which is relevant given the target audience often includes high-functioning adults.
* **Age:** The rationale and the human data center on aging brains; older individuals at the upper end of the target range, with more accumulated oxidative load and lipofuscin, are the population in which any benefit was observed.
* **Baseline oxidative and membrane status:** Because the proposed mechanism is free-radical scavenging and membrane repair, those with higher baseline oxidative stress might in theory respond more, though this has not been tested with biomarkers in controlled human work.
* **Cholinergic reserve:** Individuals with lower baseline acetylcholine activity or dietary choline intake might derive more from the DMAE-driven cholinergic contribution, but no pharmacogenetic or biomarker stratification exists to confirm this.
* **Sex-based differences:** A killifish transcriptome study found the gene-expression response to meclofenoxate was more pronounced in females; whether any human sex difference in benefit exists is unknown and untested.
## Potential Risks & Side Effects
Risks are framed for the risk-aware adult self-administering an unapproved compound, where product-quality and regulatory hazards are as important as direct pharmacology.
### Medium 🟥 🟥
#### Cholinergic Overstimulation Effects
The most commonly reported adverse effects are dose-related and stem from excess cholinergic and DMAE activity: headache, jaw tension or muscle stiffness, irritability, insomnia, and gastrointestinal upset. The mechanism is overstimulation of the acetylcholine system and the stimulant-like action of DMAE. Evidence comes from clinical trials and decades of prescription and nootropic use, where these effects were generally mild, dose-dependent, and reversible on dose reduction or discontinuation.
**Magnitude:** Generally mild and reported in a minority of users; frequency is not precisely quantified in the small trials but rises at higher doses (multi-gram daily ranges).
#### Product Quality and Mislabeling Hazard
Because centrophenoxine is sold in many markets as an unapproved "dietary supplement," products frequently misstate content. An analytical study of seven US supplements found centrophenoxine present in all but with only 1 of 7 within ±10% of the labeled amount, and daily exposures up to 752 mg. The mechanism of harm is uncertainty of actual dose, raising the chance of unintended overexposure or contamination. Evidence is direct analytical testing of marketed products.
**Magnitude:** In the analyzed sample, 6 of 7 products (86%) were inaccurately labeled; actual per-serving content ranged 79–251 mg against varying label claims, translating to maximum recommended daily exposures of 237–752 mg.
### Low 🟥
#### Excitation, Agitation, and Sleep Disruption
At higher doses, stimulation can manifest as restlessness, anxiety, agitation, or, in susceptible individuals, worsened sleep. The mechanism is the stimulant character of DMAE and cholinergic activation. Evidence is from clinical observation and case-level reports during therapeutic use; effects are typically dose-related and reversible.
**Magnitude:** Uncommon at lower doses; not quantified in controlled data but consistently described as dose-dependent and self-limiting.
### Speculative 🟨
#### Theoretical Concern from the pCPA Moiety and DMAE in Pregnancy
The para-chlorophenoxyacetic acid fragment is structurally related to chlorophenoxy herbicides, prompting theoretical concern about chronic exposure, and DMAE has raised reproductive-safety questions in animal models. No controlled human data establish harm from the released fragments at therapeutic doses, and this risk is based on structural analogy and animal signals rather than human evidence.
#### Long-Term and Cumulative Safety Unknowns
Because no long-duration, modern safety trials exist, the consequences of years of daily use for longevity purposes are genuinely unknown. Any concern about cumulative effects is mechanistic and precautionary rather than evidenced by isolated reports.
## Risk-Modifying Factors
* **Genetic and enzymatic variation:** Centrophenoxine is cleaved by esterase enzymes; while no specific polymorphism is established as clinically important, individual differences in esterase activity could in theory alter how much DMAE and pCPA are released, though this is untested.
* **Baseline biomarkers:** No specific biomarker is validated to predict who will experience side effects; those with a tendency toward cholinergic sensitivity (e.g., prior intolerance of choline-based supplements) may be more prone to headache and tension.
* **Sex-based differences:** No human data establish sex differences in side effects. Reproductive-safety concerns make pregnancy and lactation a clear avoidance setting for those who could be affected.
* **Pre-existing conditions:** People with seizure disorders, bipolar disorder, or significant anxiety may be more vulnerable to the stimulant and excitatory effects; those with major depression have historically been cautioned because DMAE has been associated with worsening of certain mood states in some reports.
* **Age:** Older adults — the primary intended users — may be more sensitive to both benefits and cholinergic side effects, and more likely to be taking interacting medications, warranting lower starting doses.
## Key Interactions & Contraindications
* **Cholinergic and cholinesterase-inhibitor drugs:** Combining centrophenoxine with acetylcholinesterase inhibitors used in dementia (donepezil, rivastigmine, galantamine) could additively increase cholinergic tone. Severity: caution/monitor; consequence: cholinergic excess (nausea, cramping, excess salivation). Mitigation: avoid stacking or use the lowest doses with monitoring.
* **Other cholinergic supplements (additive effects):** Choline donors and cholinergics taken by nootropic users — alpha-GPC, citicoline (CDP-choline), DMAE itself, huperzine A — have additive cholinergic effects and can compound headache, jaw tension, and overstimulation. Severity: caution; mitigation: do not combine multiple cholinergics; separate trials.
* **Stimulants (prescription and OTC):** Caffeine, and stimulant medications such as those used for attention disorders (e.g., methylphenidate, amphetamines), may add to the excitatory, sleep-disrupting effects. Severity: caution; consequence: anxiety, insomnia, palpitations; mitigation: limit concurrent stimulant load and avoid late-day dosing.
* **Antidepressants and mood-acting drugs:** Because DMAE has been linked to mood changes in some reports, caution is advised with antidepressants and in people with bipolar disorder, where overstimulation could be problematic. Severity: caution; mitigation: monitor mood, avoid in unstable bipolar disorder.
* **Over-the-counter anticholinergics:** OTC sleep aids and antihistamines with anticholinergic action (diphenhydramine, doxylamine) work in the opposite direction and could blunt intended effects; this is a pharmacodynamic rather than dangerous interaction. Severity: minor; mitigation: awareness only.
* **Populations who should avoid it:** Pregnant or breastfeeding individuals (reproductive-safety concerns with DMAE/pCPA); people with uncontrolled seizure disorders (epilepsy); those with unstable bipolar disorder or severe anxiety; and anyone with a known hypersensitivity to the compound. Caution in Parkinson's disease with involuntary movements, since cholinergic agents can theoretically aggravate certain motor symptoms.
## Risk Mitigation Strategies
* **Low starting dose with slow titration:** Begin at the low end (e.g., 250 mg once daily) and increase gradually only if tolerated, rather than starting at the multi-gram doses used in some trials — this directly limits the dose-related headache, jaw tension, and overstimulation that are the most common adverse effects.
* **Morning and midday dosing only:** Take doses earlier in the day and avoid late-afternoon or evening administration to prevent the insomnia and sleep disruption driven by the compound's stimulant character.
* **Avoid stacking cholinergics and stimulants:** Do not combine centrophenoxine with other choline donors (alpha-GPC, citicoline, DMAE) or with high caffeine/stimulant loads, since these have additive effects that mitigate the risk of cholinergic excess and excitation.
* **Source from tested products or compounding pharmacies:** Given that 6 of 7 marketed supplements were mislabeled in published testing, choosing third-party-tested products or pharmacist-compounded material with a certificate of analysis mitigates the documented risk of unknown or excessive actual dose.
* **Avoid in defined high-risk groups:** Withhold use in pregnancy and breastfeeding, uncontrolled epilepsy, and unstable bipolar disorder, which specifically prevents the reproductive, seizure, and mood-destabilization concerns identified in the risks section.
* **Time-limited trial with a stop rule:** Use for a defined assessment window (e.g., 8–12 weeks) with predefined success criteria and discontinue if no benefit or if side effects emerge, limiting unnecessary cumulative exposure where long-term safety is unknown.
## Therapeutic Protocol
* **Standard dosing as used by practitioners:** In clinical trials and prescription practice, centrophenoxine has been used at roughly 600 mg to 2,000 mg per day for cognitive indications; nootropic-community practice typically uses a lower range of around 250–1,000 mg per day, starting low and titrating. The 600 mg twice-daily regimen from the healthy-elderly trial is a commonly cited reference point.
* **Competing approaches:** A conventional medical approach treats centrophenoxine as a prescription agent for diagnosed cognitive decline under physician supervision, while an integrative/self-experimentation approach uses lower over-the-counter doses for general cognitive and longevity goals. Neither is presented here as the default; the evidence base does not clearly favor one framing.
* **Originators and popularizers:** The Hungarian gerontology group led by Imre Zs.-Nagy popularized the longevity and membrane-protection framing, while the broader nootropic community (reflected in references such as Nootropics Expert) popularized the lower-dose cognitive-enhancement use.
* **Best time of day:** Morning, or morning and midday for split dosing, to align with its stimulant character and avoid sleep disruption.
* **Half-life consideration:** The parent ester is hydrolyzed within minutes, so the practical duration of action depends on the released DMAE; split dosing (e.g., morning and early afternoon) is often used to maintain effect across the day rather than a single large dose.
* **Single versus split dosing:** Split dosing is generally preferred over a single large dose to smooth effects and reduce peak-related side effects such as headache and tension.
* **Genetic polymorphisms:** No validated pharmacogenetic markers (such as APOE4, an Alzheimer's-risk gene variant, or COMT, which affects dopamine breakdown) guide centrophenoxine dosing; esterase-activity differences are plausible but not actionable with current testing.
* **Sex-based differences:** No human dosing differences by sex are established; an animal transcriptome study suggested a stronger female response, but this does not translate into a human dosing recommendation.
* **Age-related considerations:** Older adults, the main intended users, should generally start at the lower end given greater sensitivity and more concurrent medications.
* **Baseline biomarkers:** No biomarker is validated to set the dose; baseline cognitive testing can instead serve as a personal reference to judge response.
* **Pre-existing conditions:** Lower doses and closer caution are warranted in those with anxiety, sleep problems, seizure history, or mood disorders, as covered in the interactions section.
## Discontinuation & Cycling
* **Lifelong versus short-term:** There is no evidence establishing a need for lifelong use; most human data come from defined treatment courses of weeks to months, and longevity use is best approached as a series of evaluated trials rather than indefinite continuous dosing given the absence of long-term safety data.
* **Withdrawal effects:** No characteristic withdrawal syndrome has been described; the short half-life of the parent compound and lack of physical-dependence reports suggest discontinuation is generally uneventful.
* **Tapering:** Formal tapering is not described as necessary; because effects are not dependence-forming, stopping can be done directly, though gradual reduction is reasonable if higher doses were used.
* **Cycling:** Some nootropic users cycle centrophenoxine (e.g., several weeks on, then a break) to limit tolerance and cumulative exposure, but no controlled data show that cycling preserves efficacy or improves safety; it is a precautionary practice rather than an evidence-based one.
* **Practical discontinuation:** If no benefit is observed within a defined trial window or if side effects emerge, discontinuation is straightforward and the most reasonable course given the limited evidence for sustained benefit.
## Sourcing and Quality
* **Regulatory form varies by market:** Centrophenoxine is a prescription drug in some countries (and historically marketed as Lucidril, Helfergin, and Cerutil) but is sold elsewhere, including the US, as an unapproved "dietary supplement," so source and legal status differ sharply by region.
* **Documented mislabeling risk:** Published analysis found that only 1 of 7 US supplement products contained centrophenoxine within ±10% of the labeled amount, making third-party testing essential rather than optional when products are bought over the counter.
* **What to look for:** Prefer products with a recent certificate of analysis confirming identity and quantity, ideally from independent third-party laboratories; for pharmaceutical-grade material, a compounding pharmacy working from a prescription provides better dose certainty than consumer supplements.
* **Reputable channels:** Where legal, pharmacist-compounded centrophenoxine or established pharmaceutical brands (the historical Lucidril/Helfergin lineage) offer more reliable quality than unverified online supplement vendors.
* **Storage and form:** The compound is typically supplied as the hydrochloride salt; because the ester is moisture-sensitive and hydrolyzes readily, products should be kept dry and used within their labeled shelf life to preserve potency.
## Practical Considerations
* **Time to effect:** Acute stimulant-like and cognitive effects may be noticed within hours to days, but the memory effects seen in trials emerged over weeks to months of continuous use, so a meaningful personal trial requires at least 8–12 weeks.
* **Common pitfalls:** Starting at the high multi-gram doses used in old trials, stacking multiple cholinergics, dosing late in the day, and buying mislabeled supplements are the most frequent mistakes; expecting dramatic cognitive gains in already-healthy young adults is also common and usually unmet by the evidence.
* **Regulatory status:** In the US, centrophenoxine is not FDA-approved for any indication and its sale as a dietary supplement is not a lawful approval; users should understand they are taking an unapproved drug. In several other countries it remains a prescription medicine.
* **Cost and accessibility:** Centrophenoxine is relatively inexpensive and widely available online, but accessibility comes with the documented quality and legality caveats rather than any difficulty of supply.
## Interaction with Foundational Habits
* **Sleep:** The interaction is direct and potentially negative — the compound's stimulant character and cholinergic activation can disrupt sleep onset if taken late in the day; the practical mitigation is to confine dosing to morning and midday and avoid evening use.
* **Nutrition:** The interaction is indirect and potentially potentiating — because the active DMAE feeds the acetylcholine pathway, adequate dietary choline (eggs, liver, fish) supports the cholinergic system, while combining with additional choline supplements risks overstimulation; taking it with food may reduce gastrointestinal upset.
* **Exercise:** The interaction is largely indirect with no strong evidence of benefit or harm — there is no established effect on hypertrophy or endurance, and no specific timing relative to workouts is supported; any perceived focus benefit is anecdotal rather than demonstrated.
* **Stress management:** The interaction is direct and bidirectional — in some users the mild stimulation can increase anxiety or restlessness, working against stress management, while others report improved mental clarity; those prone to anxiety should monitor closely and reduce dose if stress or agitation rises, with no clear evidence of an effect on cortisol.
## Monitoring Protocol & Defining Success
Because centrophenoxine has a benign general safety profile but uncertain long-term effects, baseline assessment focuses on a brief safety and cognitive reference rather than an extensive lab panel, and ongoing monitoring centers on tolerability and self-tracked cognitive change.
Before starting, it is reasonable to establish a baseline that captures general health status and a personal cognitive reference point, so that any change can be judged against it rather than impression alone.
Ongoing monitoring should follow a simple cadence — a tolerability check at roughly 1–2 weeks after starting or after any dose increase, a cognitive and side-effect review at about 8–12 weeks to judge whether the trial is worth continuing, and then a periodic review every 6–12 months for anyone using it long term.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| Blood pressure & resting heart rate | BP <120/80 mmHg; HR 60–80 bpm | Detects stimulant-related cardiovascular effects | BP (blood pressure) and HR (heart rate, in bpm — beats per minute); check at baseline and after dose increases; measure rested and seated |
| Sleep quality (tracked) | Stable, undisrupted sleep | Catches the most common functional side effect | Subjective log or wearable; compare to pre-treatment baseline |
| Comprehensive metabolic panel (CMP) | ALT/AST <25 U/L; fasting glucose 75–85 mg/dL; eGFR >90 mL/min/1.73m² | General safety screen for long-term users | A routine blood test of liver, kidney, and electrolyte status; ALT/AST are liver enzymes and eGFR (estimated glomerular filtration rate) gauges kidney function; functional targets are tighter than the conventional "within reference range" (e.g., ALT/AST up to ~40 U/L); optional baseline and annual; no specific organ toxicity is established but prudent for chronic use |
| Mood / anxiety self-rating | Stable or improved vs. baseline | DMAE can affect mood in susceptible people | Brief validated self-rating; relevant for those with anxiety or bipolar history |
Qualitative markers are often more informative than labs for this compound:
* **Memory and recall:** Subjective ease of recalling names, lists, and recently learned information, ideally anchored to a simple repeatable self-test.
* **Mental clarity and focus:** Day-to-day sense of alertness and concentration.
* **Energy and mood:** Whether the mild stimulation feels like clean energy or tips into jitteriness, anxiety, or irritability.
* **Sleep:** Time to fall asleep and overall sleep quality relative to baseline.
* **Headache or jaw tension:** Presence of the characteristic cholinergic side effects as an early signal to lower the dose.
## Emerging Research
* **Hepatic encephalopathy combination trial:** A registered trial evaluating coenzyme Q10 and meclofenoxate in hepatic encephalopathy (confusion from liver failure) was listed with a planned enrollment of 300 participants — [NCT03961087](https://clinicaltrials.gov/study/NCT03961087); its status is listed as unknown, illustrating how little active, registered clinical work exists for this compound.
* **Aging-brain transcriptomics:** A 2022 study mapped how lifelong meclofenoxate treatment altered gene expression in the aging brain of a short-lived killifish, finding it compensated for some age-related declines in neuronal-activity genes but did not prevent inflammatory aging signatures — [Bakhtogarimov et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35269638/); this could either strengthen the case by clarifying mechanism or weaken it by showing limited, mixed effects.
* **Protein-aggregation mechanism:** In vitro work showed meclofenoxate reduced aggregation of alpha-synuclein, the protein implicated in Parkinson's disease, suggesting a possible neuroprotective avenue — [Parui et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36880185/); this is a laboratory finding that motivates, but cannot establish, a disease benefit.
* **Supplement-quality surveillance:** Analytical research quantifying mislabeling in marketed centrophenoxine supplements continues to shape the practical risk picture — [Cohen et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35959800/); such work weakens the case for current consumer products even as it leaves the underlying pharmacology open.
* **Future directions that could change understanding:** The decisive missing evidence is a modern, adequately powered, long-duration randomized trial in older adults measuring both cognition and aging biomarkers; until such a study exists, the longevity case rests on dated and animal data, and either a confirmatory or a null modern trial would substantially shift current understanding.
## Conclusion
Centrophenoxine is a synthetic compound from the late 1950s that pairs a choline-related building block with a carrier molecule, and it has long been used in several countries to treat age-related memory decline. Longevity interest stems from older findings that it lowers the brownish "age pigment" that builds up in long-lived cells and protects cell membranes from oxidative damage, with a handful of small, dated human studies hinting at modest memory gains in older adults.
The honest picture is one of promise that was never properly tested. The most consistent human signal — better delayed recall in the elderly — comes from small, old trials, and broader claims about extending lifespan or protecting against brain disease rest on animal and laboratory work rather than controlled human outcomes. The compound is generally well tolerated, with mostly mild, dose-related effects, but its long-term safety is genuinely unknown, and a major practical hazard is that many products sold as supplements are mislabeled and unapproved.
For someone weighing it as a longevity tool, the takeaway is that the story of how it might work is interesting and the short-term risk modest, while the proof of meaningful benefit remains thin and unconfirmed by modern evidence. Where the evidence is uncertain, that uncertainty is real and central rather than incidental.
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**